Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR2A | P27037 | 14/20 | 0.43 |
| ▸ | TGFBR2 | P37173 | 12/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561513 | 0.84 | GRM2 (0.43) | MAPTSYKGRM2CYP19A1 | |
| SCHEMBL561555 | 0.75 | PIK3CD (0.56) | ACVR2ATGFBR2TGFBR1MAPT | |
| SCHEMBL29467455 | 0.71 | KMT2A (0.41) | — | |
| SCHEMBL28728560 | 0.71 | KMT2A (0.41) | — | |
| SCHEMBL561748 | 0.71 | TRPA1 (0.47) | DYRK1A | |
| SCHEMBL27111217 | 0.68 | MAPT (0.47) | ACVR2ATGFBR2MAPTDYRK1ASYK | |
| SCHEMBL30303232 | 0.67 | CCR4 (0.49) | MAPT | |
| SCHEMBL561004 | 0.67 | PDE2A (0.49) | MAPT | |
| SCHEMBL29467448 | 0.67 | PDE2A (0.49) | MAPT | |
| SCHEMBL129887 | 0.67 | CCR4 (0.49) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653098-B2 | Pyrazolopyridine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653098-B2 | Pyrazolopyridine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653098-B2 | Pyrazolopyridine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| EP-2356117-B1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2356117-B1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20120035208-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2012-02-09 | — | — | US | disclosed |
| US-20120035208-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2012-02-09 | — | — | US | disclosed |
| US-20120035208-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2012-02-09 | — | — | US | disclosed |
| EP-2356117-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010059788-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035208-A1 | PYRAZOLOPYRIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PI4KA | ACVR2A 3774/4885TGFBR2 3748/4885TGFBR1 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.